NASDAQ$NUWE

Nuwellis Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Briefing

Nuwellis reported modest revenue growth and improved gross margin but continued to post a quarterly operating loss as it focused on operational restructuring and commercial execution.

Nuwellis generated modest revenue growth in Q4 2025 driven by higher console sales and improved pricing, which also lifted gross margin. However, the company continued to operate at a loss as operating expenses exceeded gross profit while maintaining a limited cash position.

  • Q4 revenue increased to $2424000, up 4% year-over-year.
  • Gross margin improved significantly to 68.2% from 58.4% in the prior year quarter.
  • Net loss attributable to common shareholders was $2421000 for the quarter.
  • Cash and cash equivalents at quarter end totaled $1085000.

Headline financials

Total Revenue

$2.42M

Previous: $2.32M+4.4%
EPS (adj)

-$1.50

Previous: -$0.44-240.9%
Gross Margin

68.2%

Previous: 58.4%+16.8%
Weighted Avg Shares

1.6M

Previous: 80.0K+1917.4%
Net Income

-$2.42M

Previous: -$1.47M-64.9%
Operating Income

-$2.44M

Previous: -$2.39M-2.3%
Gross Profit

$1.65M

Previous: $1.36M+22.1%

Revenue & EPS history

Nuwellis · Revenue · Quarterly

$2.42M

Q4 2025+4.4%vs Q4 2024
Beat estimate in 4 of 14 quarters(29%)
ActualEstimate

Forward guidance

Nuwellis expects to focus on commercial execution, integration of the Rendiatech acquisition, and continued development of pediatric technologies while strengthening its capital position.

Tailwinds

  • Acquisition of Rendiatech expected to expand the cardiorenal product portfolio.
  • Improving utilization trends in key product lines.
  • Strong gross margin expansion in the quarter.
  • Capital position strengthened through private placement financing.
  • Development progress on Vivian pediatric solution supported by NIH grant funding.

Headwinds

  • Company continues to report operating and net losses.
  • Limited cash reserves relative to ongoing operating needs.
  • Revenue scale remains small with modest growth.
  • Reliance on external financing to support operations.
  • Execution risk around integrating acquisitions and expanding product adoption.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-5.5%

Avg return

Earnings day

-10.5%

Avg return

5 days after

-16.7%

Avg return

30 days after

28%

15 / 54 earnings

Positive

+51.9%

Q1 2024

Best reaction

-29.9%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-5.0%
Q4 2025+2.4%-2.3%-16.3%
Q3 2025-3.4%-11.9%-18.0%
Q2 2025+0.4%+8.4%-24.0%
Q1 2025-3.1%-5.1%-68.7%
Q4 2024-4.0%-7.9%-25.4%
Q3 2024+6.6%-0.6%-28.2%
Q2 2024-14.3%-30.2%-46.4%
Q1 2024+51.9%+47.1%+29.4%
Q4 2023-20.7%-18.3%-36.7%
Q3 2023-10.0%-12.9%-14.3%
Q2 2023-5.1%-3.0%-22.2%
Q1 2023-29.9%-37.8%-34.6%
Q4 2022-5.1%-6.5%-41.2%
Q3 2022-19.6%-16.7%-50.0%
Q2 2022-6.5%-4.2%+23.9%
Q1 2022+1.0%+2.9%-7.4%
Q4 2021-1.2%-6.1%+2.0%
Q3 2021-17.0%-13.2%-33.3%
Q2 2021+9.6%+7.9%+3.0%
Q1 2021-14.6%-8.9%+6.6%
Q4 2020+5.7%-6.2%-21.3%
Q3 2020-7.8%-7.0%+14.1%
Q2 2020-16.0%-32.0%-68.0%
Q1 2020-9.6%-14.6%+2.4%
Q4 2019-28.8%-33.9%-29.0%
Q3 2019-15.0%-23.0%-16.0%
Q2 2019-1.2%+2.0%+0.4%
Q1 2019-13.3%-13.3%-24.9%
Q4 2018-12.6%-25.6%-69.8%
Q3 2018+2.8%+4.7%-21.7%
Q2 2018-26.4%-37.4%-23.9%
Q1 2018-17.1%-18.8%-23.3%
Q4 2017-15.5%-25.7%-21.0%
Q3 2017-12.8%-15.6%-47.3%
Q2 2017-4.0%-13.3%-6.7%
Q1 2017-9.5%-1.4%-9.5%
Q4 2016-5.3%-12.0%-58.0%
Q3 2016-5.0%-5.0%+190.0%
Q2 2016-14.9%-16.0%-17.0%
Q1 2016+1.5%
Q4 2015-15.9%
Q3 2015-1.2%
Q2 2015+0.7%
Q1 2015-3.5%
Q4 2014-0.2%
Q3 2014-17.5%
Q2 2014+23.9%
Q1 2014+3.2%
Q4 2013+2.1%
Q1 2013+6.2%
Q4 2012+2.6%
Q2 2012-7.6%
Q4 2011+0.0%
Q3 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro